Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical company making and marketing generic formulations, APIs and branded generics in India while exporting to the U.S., Europe, ROW and country subsidiaries, with USFDA‑approved manufacturing and a significant ANDA pipeline (cumulative 270 filings and 212 cumulative final approvals).

Q3 FY26 revenue grew 11% year‑on‑year to INR 1,876 crore, with gross margin of 72% and EBITDA before R&D at 25% of revenue; PAT before exceptional items rose 21% year‑on‑year to INR 168 crore, showing resilient operating leverage despite U.S. pricing pressure and higher R&D spend.

R&D intensity is high—around 8–9% of revenue with quarterly R&D at INR 165 crore and full‑year guidance of INR 600–650 crore—supporting a strategy focused on complex injectables, ophthalmics, peptides and early‑entry ANDA opportunities including First‑to‑File and differentiated launches.

Geographic diversification is advancing: U.S. grew modestly (6% in Q3) while EROW expanded 36% by region, API and Pfizer collaborations showing variable performance; management expects U.S. mid‑teens potential over coming years and aims to commercialize its first U.S. branded product (Pivya) in Q4 FY26.